Lead Product(s) : Tranexamic Acid
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hyloris Enrolls First Patient in Phase 3 for Proprietary Mouth Rinse for Dental Bleeding
Details : Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.
Product Name : HY-004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable